Document Type: Original Research

Authors

1 Faculty of Medicine, Airlangga University, Jawa, Indonesia

2 Department of Clinical Pathology, Faculty of Medicine, Airlangga University, Jawa, Indonesia

3 Department of Public Health, Faculty of Medicine, Airlangga University, Jawa, Indonesia

4 4. Department of Biochemistry and Molecular Biology, Faculty of Medicine, Airlangga University, Jawa, Indonesia

Abstract

Background & Objective:  FLT3-ITD has been recently used as a molecular prognostic marker for risk classification in acute myeloid leukemia (AML) therapy. In this study we aimed to investigate the association of FLT3-ITD gene mutation with bone marrow blast cell count, CD34 expression as malignant cell burden, cyclin D1 and Bcl-xL expressions as indexes of cell proliferation and anti-apoptosis and human equilibrative nucleoside transporter 1 (hENT1) expression as cytarabine transporter during AML treatment.
Methods:  We investigated FLT3-ITD mutations, bone marrow blast cell count, CD34, cyclin D1, Bcl-xL and hENT1 expression in bone marrow aspirates from 22 de novo AML patients in a cross sectional study.
Results:  FLT3-ITD mutations were observed in 5 out of 22 de novo AML patients (22.7%). Patient with FLT3-ITD mutations had higher blast cell counts (79.5% vs 56.1%, p =0.004). In patients with FLT3-ITD mutations, CD34 and cyclin D1 expressions were higher (MFI 328.80 vs 25.78, p =0.003 and MFI 74.51 vs 57.15 p =0.005) than the patients without mutations. hENT1 expression in AML with FLT3-ITD mutation was lower (MFI 29.64 versus 56.32, p =0.0000) than in mutation-free AML. There was no significant difference in Bcl-xL expression between patients with and without mutations (p =0.61).
Conclusion:  A significant association was found between FLT3-ITD gene mutations in AML patients with bone marrow blast cell count, CD34, cyclin D1 and hENT1 expressions, however no association was obtained with Bcl-xL expression. These findings support the role of such mutation in pathogenesis of AMLand its contribution in rearrangement of standard therapy with cytarabine in management of AML.

Keywords

Main Subjects

  1. Seer cancer statistic review (CSR) 1975 - 2014 [Internet]. National Cancer Institute. 2017 [cited September 29, 2017]. Available from: http://seer.cancer.gov/csr/1975-2014/.
  2. Yohe S. Molecular genetic markers in acute myeloid leukemia. J Clin Med. 2015;4:460-78. [DOI:10.3390/jcm4030460] [PMID] [PMCID]
  3. Ferrara F, Palmieri S, Leoni F. Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol. 2008;66:181-93. [DOI:10.1016/j.critrevonc.2007.09.008] [PMID]
  4. Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia : biology and treatment. Oncol Rev. 2012;6(1):64-74. [DOI:10.4081/oncol.2012.e8] [PMID] [PMCID]
  5. Patnaik MM. The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk Lymphoma. 2018;59:1-15. [DOI:10.1080/10428194.2017.1399312] [PMID]
  6. Schuurhuis GJ, Kedler A, Terwijn M, Rutten AP, Smit L, Zweegman S, et al. The prognostic value of CD34 expression in acute myeloid leukemia. A mystery solved. Blood. 2010;116:2725. [DOI:10.1182/blood.V116.21.2725.2725]
  7. Zhu HH, Liu Y-R, Jiang H, Lu J, Qin Y-Z, Jiang Q, et al. CD34 expression on bone marrow blast is a novel predictor of poor prognosis independent of FLT3-ITD in acute myeloid leukemia with NPM1 mutation. Jleukres. 2013;37(6):624-30. [DOI:10.1016/j.leukres.2013.02.007] [PMID]
  8. Haferlach T, Bacher U, Alpermann T, Haferlach C, Kern W, Schittger S. Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal kariotype. JLeukres. 2012;36:51-8. [DOI:10.1016/j.leukres.2011.04.026] [PMID]
  9. Catala A, Pastor-Anglada M, Caiedes-Cardenas L, Malatesta R, RIves S, Vega-Garcia N, et al. FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016;7(31):49786-99. [DOI:10.18632/oncotarget.10448] [PMID] [PMCID]
  10. Jin G, Matsushita H, Asai S, Tsukamoto H, Ono R, Nosaka T, et al. FLT3-ITD induces Ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. BiochemBiophysResCommun. 2009;390:1001-6. [DOI:10.1016/j.bbrc.2009.10.094] [PMID]
  11. Gorczyca W, Emmons FN. Immunophenotyping. In: Gorczyca W, Emmons FN, editors. Atlas of differential diaagnosis in neoplastic hematopathology. 2nd ed. UK: Informa UK Ltd; 2008. p. 42-9. [DOI:10.3109/9781439806487]
  12. Licinio MA, Silva MCSd. Importance of detecting FLT3 and NPM1 gene mutations in acute myeloid leukemia - World Health Organization classification 2008. Rev Bras Hematol Hemoter. 2010;32(6):476-81. [DOI:10.1590/S1516-84842010000600012]
  13. Sarojam S, VIjay S, Raveendran S, Sreedharan J, Narayanan G, Sreedharan H. FLT3 Mutation as a Significant Prognostic Marker in de novo Acute Myeloid Leukemia Patients: Incidence, Distribution and Association with Cytogenetic Findings in a Study from South India. MEJC. 2014;5(4):185-96.
  14. Rombouts E. Internal tandem duplications in the Flt3-gene in human acute myeoid leukemia. Rotterdam: Erasmus Medical Center; 2004.
  15. Notopuro PB, Notopuro H, Budiwijono I, Adhipireno P. The difference in initial leukocyte count, bone marrow blast cell count, and CD34 expression in patients with acute myeloid leukemia with and without NPM1 gene mutation. IJBC. 2017; Jun 10;9(2):44-7
  16. Kumsaen P, Fucharoen G, Sirijerachai C, Chainansamit S-o, Wisanuyothin N, Kuwatjanakul P, et al. FLT3-ITD Mutations in Acute Myeloid Leukemia Patients in Northeast Thailand. Asian Pac J Cancer Prev. 2016;17(9):4395-9.
  17. Wang L, Xu Wl, Meng Ht, Qian Wb, Mai Wy, Tong Hy, et al. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics. J Zhejiang Univ-Sci B ( Biomed & Biotechnol ). 2010;11(10):762-70. [DOI:10.1631/jzus.B1000052] [PMID] [PMCID]
  18. Yunus NM, Johan MF, Al-Jamal HAN, Husin A, Hussein AR, Hassan R. Characterization and Clinical SIgnificance of FLT3-ITD and non-ITD in Acute Myeloid Leukemia Patients in Kelantan, Northeast Peninsular Malaysia. Asian Pac J Cancer Prev. 2015;16(12):4869-72. [DOI:10.7314/APJCP.2015.16.12.4869] [PMID]
  19. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia : association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35. [DOI:10.1182/blood.V99.12.4326] [PMID]
  20. Molica M, Breccia M. FLT3-ITD in acute promyelocytic leukemia: clinical distinct profile but still controversial prognosis. Jleukres. 2015;39(4):397-9. [DOI:10.1016/j.leukres.2015.01.004] [PMID]
  21. Alejandro F, Rangel L, Chavez-Valencia V. FLT3-ITD and its current role in acute myeloid leukemia. Med Oncol. 2017;34:114. [DOI:10.1007/s12032-017-0970-x] [PMID]
  22. Aref S, Mabed M, El-Sherbiny M, Selim T, Metwaly A. Cyclin D1 expression in acute leukemia. Hematology. 2006;11(1):31-4. [DOI:10.1080/10245330500322321] [PMID]
  23. Pallis M, Zhu Y-M, Russell N. BCL-XL is heterogeneously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia. 1997;11:945-9. [DOI:10.1038/sj.leu.2400705] [PMID]
  24. Elyamany G, Awad M, Fadalla K, Albalawi M, Shahrani MA, Abdulaaly AA. Frequency and prognostic relevance of FLT3 mutations in Saudi acute myeloid leukemia patients. Adv Hematol. 2014;2014:1-7. [DOI:10.1155/2014/141360] [PMID] [PMCID]
  25. Ibrahim EK, Assem MM, Amin AI, Kamel M, Meligui YME, Metwally AM. FLT3 internal tandem duplication mutation, cMPL and CD34 expressions predict low survival in acute myeloid leukemia patients. Ann clin lab sci. 2016;46(6):592-600.
  26. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752-61. [DOI:10.1182/blood.V98.6.1752] [PMID]
  27. Anglada MP, Torras SP. Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. Front Pharmacol. 2015;6(13):1-14. [DOI:10.3389/fphar.2015.00013] [PMID] [PMCID]
  28. Chabner BA. Antimetabolites: fluoropyrimidines and other agents. In: Chabner BA, Lynch TJ, Longo DL, editors. Harrison's Manual of Oncology. United States of America: McGraw-Hill Companies Inc; 2008. p. 1-17.
  29. Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metast Rev. 2007;26:85-110. [DOI:10.1007/s10555-007-9044-4] [PMID]
  30. Safaie A, Monabati A, Mokhtari M, Safavi M, Solhjoo F. Evaluation of the CD123 Expression and FLT3 Gene Mutations in Patients with Acute Myeloid Leukemia. Iran J Pathol. 2018;13(4):438-46.
  31. Aleem E, Arceci RJ. Targetting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol. 2015;3(16):1-22. [DOI:10.3389/fcell.2015.00016] [PMID] [PMCID]
  32. Eltzshig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schonfeld C, et al. HIF-1 dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med. 2005;202(11):1493-505. [DOI:10.1084/jem.20050177] [PMID] [PMCID]
  33. Huang W, Zeng X, Shi Y, Liu M. Functional characterization of human equilibrative nucleoside transporter 1. Protein Cell. 2017;8(4):284-95. [DOI:10.1007/s13238-016-0350-x] [PMID] [PMCID]
  34. Mehrazma M, Rafsanjani KA, Torkamanipoor B. Correlation between soluble vascular endothelial growth factor A and its receptor 1 with response to chemotherapy in acute leukemia in children. Iran J Pathol. 2008;3(4):179-82.
  35. Wan H, Zhu J, Chen F, Huang H, Han X, Zhong L, et al. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res. 2014;33(90):1-10. [DOI:10.1186/s13046-014-0090-9] [PMID] [PMCID]